Search
BHV-1300
go.drugbank.com/drugs/DB22673InvestigationalBHV-1300 is a IgG1,2,4 selective degrader being investigated for the treatment of Grave's disease.
Linsitinib
go.drugbank.com/drugs/DB06075InvestigationalAn orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. … IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.
KAND567
go.drugbank.com/drugs/DB16511InvestigationalKAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation . Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as ...
Irsogladine
go.drugbank.com/drugs/DB13056InvestigationalIrsogladine is under investigation in clinical trial NCT02581696 (The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers).
Categories: Compounds used in a research, industrial, or household settingBizelesin
go.drugbank.com/drugs/DB12352InvestigationalBizelesin has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Categories: Compounds used in a research, industrial, or household settingImeglimin
go.drugbank.com/drugs/DB12509InvestigationalImeglimin has been used in trials studying the treatment of Type 2 Diabetes Mellitus.
Categories: Drugs Used in DiabetesRGX-181
go.drugbank.com/drugs/DB17942ExperimentalDeveloped by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.[L47072] … RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene.
Gavestinel
go.drugbank.com/drugs/DB06741ExperimentalGavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is orally bioavailable and active in vivo. … Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).
Sorbitan monooleate
go.drugbank.com/drugs/DB19493ExperimentalSorbitan monooleate is a small molecule drug. Sorbitan monooleate has a monoisotopic molecular weight of 428.31 Da.
Categories: Compounds used in a research, industrial, or household setting